DE69916881D1 - Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure - Google Patents

Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure

Info

Publication number
DE69916881D1
DE69916881D1 DE69916881T DE69916881T DE69916881D1 DE 69916881 D1 DE69916881 D1 DE 69916881D1 DE 69916881 T DE69916881 T DE 69916881T DE 69916881 T DE69916881 T DE 69916881T DE 69916881 D1 DE69916881 D1 DE 69916881D1
Authority
DE
Germany
Prior art keywords
indolalcanic
antihypertriglyceridemic
antihyperglycemic
antiangiogenic
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69916881T
Other languages
English (en)
Other versions
DE69916881T2 (de
Inventor
Janet Sredy
Jorge Jacot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Pharmaceutical Discovery Inc
Institutes for Pharmaceutical Discovery Inc
Original Assignee
Institute for Pharmaceutical Discovery Inc
Institutes for Pharmaceutical Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Pharmaceutical Discovery Inc, Institutes for Pharmaceutical Discovery Inc filed Critical Institute for Pharmaceutical Discovery Inc
Publication of DE69916881D1 publication Critical patent/DE69916881D1/de
Application granted granted Critical
Publication of DE69916881T2 publication Critical patent/DE69916881T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/428Thiazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE69916881T 1998-12-01 1999-12-01 Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure Expired - Lifetime DE69916881T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01
US110395P 1998-12-01
PCT/US1999/028483 WO2000032180A2 (en) 1998-12-01 1999-12-01 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids

Publications (2)

Publication Number Publication Date
DE69916881D1 true DE69916881D1 (de) 2004-06-03
DE69916881T2 DE69916881T2 (de) 2005-02-03

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69916881T Expired - Lifetime DE69916881T2 (de) 1998-12-01 1999-12-01 Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure

Country Status (30)

Country Link
US (5) US6555568B1 (de)
EP (1) EP1135124B1 (de)
JP (1) JP2002531398A (de)
KR (1) KR20010086075A (de)
CN (1) CN1368883A (de)
AP (1) AP2001002146A0 (de)
AT (1) ATE265210T1 (de)
AU (1) AU770925B2 (de)
BG (1) BG105531A (de)
BR (1) BR9915882A (de)
CA (1) CA2385845A1 (de)
CZ (1) CZ20011864A3 (de)
DE (1) DE69916881T2 (de)
DZ (1) DZ2953A1 (de)
EE (1) EE200100296A (de)
HK (1) HK1046372A1 (de)
HU (1) HUP0104953A3 (de)
ID (1) ID30037A (de)
IL (1) IL143247A0 (de)
MX (1) MXPA02003118A (de)
NO (1) NO20012690L (de)
OA (1) OA12035A (de)
PL (1) PL349016A1 (de)
SK (1) SK7352001A3 (de)
TN (1) TNSN99224A1 (de)
TR (1) TR200101539T2 (de)
TW (1) TW584560B (de)
WO (1) WO2000032180A2 (de)
YU (1) YU40101A (de)
ZA (1) ZA200104126B (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02003122A (es) * 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
BR0316584A (pt) 2002-12-10 2005-10-04 Wyeth Corp Derivados de ácido acético indol oxo-acetil amino substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
JP2006510673A (ja) 2002-12-10 2006-03-30 ワイス プラスミノゲンアクティベータインヒビター1(pai−1)のインヒビターとしての、アリール、アリールオキシ、および、アルキルオキシ置換1h−インドール−3−イルグリオキシル酸誘導体
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
DE60306548T2 (de) 2002-12-10 2007-06-21 Wyeth Substituierte 3-carbonyl-1-yl-essigsäure-derivate als plasminogen aktivator inhibitor(pai-1) inhibitoren
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4828414B2 (ja) * 2003-04-28 2011-11-30 ニツポネツクス・インコーポレーテツド インドール酢酸誘導体および薬剤としてのそれらの使用
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006023865A1 (en) 2004-08-23 2006-03-02 Wyeth Oxazolo-naphthyl acids as plaminogen activator inhibtor type-1 (pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases
JP2008521829A (ja) * 2004-11-30 2008-06-26 プレキシコン,インコーポレーテッド Ppar活性化合物
WO2006060535A2 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
AU2006279496A1 (en) 2005-08-17 2007-02-22 Wyeth Substituted indoles and use thereof
US20070072904A1 (en) * 2005-09-07 2007-03-29 Jack Lin PPAR active compounds
JP5270542B2 (ja) 2006-07-22 2013-08-21 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
ES2442717T3 (es) 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Crth2アンタゴニスト活性を有する化合物
EP3563842A1 (de) 2009-04-29 2019-11-06 Amarin Pharmaceuticals Ireland Limited Pharmazeutische zusammensetzungen mit epa und einem kardiovaskulären mittel sowie verfahren zur verwendung davon
EP2970119B1 (de) * 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Neuartige indolderivate als antidiabetika
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
IL80475A (en) 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4960785A (en) * 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
WO1991009019A1 (en) 1989-12-15 1991-06-27 Pfizer Inc. Substituted oxophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−3−酢酸誘導体、その製造法と用途
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) * 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
MXPA02003122A (es) * 1998-03-31 2004-04-21 Inst For Pharm Discovery Inc Acidos indolalcanoicos substituidos.
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
US6555568B1 (en) 2003-04-29
CZ20011864A3 (cs) 2002-03-13
EP1135124B1 (de) 2004-04-28
US6964980B2 (en) 2005-11-15
US20030216452A1 (en) 2003-11-20
YU40101A (sh) 2005-07-19
ID30037A (id) 2001-11-01
EE200100296A (et) 2003-02-17
BR9915882A (pt) 2001-08-21
SK7352001A3 (en) 2002-06-04
EP1135124A2 (de) 2001-09-26
CN1368883A (zh) 2002-09-11
WO2000032180A2 (en) 2000-06-08
NO20012690D0 (no) 2001-05-31
BG105531A (en) 2001-12-31
CA2385845A1 (en) 2000-06-08
ATE265210T1 (de) 2004-05-15
TW584560B (en) 2004-04-21
HK1046372A1 (zh) 2003-01-10
AP2001002146A0 (en) 2001-06-30
WO2000032180A3 (en) 2000-11-16
JP2002531398A (ja) 2002-09-24
PL349016A1 (en) 2002-06-17
HUP0104953A2 (hu) 2002-07-29
DE69916881T2 (de) 2005-02-03
HUP0104953A3 (en) 2002-08-28
DZ2953A1 (fr) 2004-03-15
US20120065203A1 (en) 2012-03-15
IL143247A0 (en) 2002-04-21
TNSN99224A1 (fr) 2005-11-10
ZA200104126B (en) 2002-05-21
AU2161600A (en) 2000-06-19
US20060074114A1 (en) 2006-04-06
US20100324105A1 (en) 2010-12-23
KR20010086075A (ko) 2001-09-07
TR200101539T2 (tr) 2001-12-21
MXPA02003118A (es) 2004-04-21
NO20012690L (no) 2001-07-27
AU770925B2 (en) 2004-03-11
OA12035A (en) 2006-05-02

Similar Documents

Publication Publication Date Title
DE69916881D1 (de) Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure
NO971926D0 (no) Polymeriske sårlegende akseleratorer
DE69919160D1 (de) Wundverband
ATE239005T1 (de) (4-sulfonylamino)-tetrahydropyran-4-carbonsäure hydroxamiden
ATE269861T1 (de) Substituierte indolalkansäure
DK1053020T3 (da) Absorberbare mikropartikler
NO20006116D0 (no) Nye 3-arylpropionsyrederivater og -analoger
DE69940034D1 (de) Chirurgischer Retraktor
DE69710041D1 (de) Wundverband und herstellungsverfahren dafür
DK1100769T3 (da) Aminomethylcarboxylsyrederivater
DE69923810D1 (de) Blutstillendes Mittel
ID28050A (id) Alat kesehatan
DE69626993T2 (de) Wundbehandlungszusammensetzung
DE50001690D1 (de) Chirurgisches Cerclageband
DE69941047D1 (de) Wundverband
IS4898A (is) Sáraumbúðir
IS5562A (is) Nýjar díhýdroxýhexanósýru afleiður
PT878467E (pt) Acidos 6-aminotetra-hidroisoquinolinacarboxilicos e 7-aminotetra-hidroisoquinolinacarboxilicos substituidos
DE69521471D1 (de) Absorbierbares Nahtmaterial
FI953615A0 (fi) Haavanparannuskoostumus
ATE219050T1 (de) Hydroxamsäure-derivate
DE69933597D1 (de) Hebezeug
NO992607L (no) System med sårhelende virkning
DK75998A (da) Sårbandage
SE9704575D0 (sv) Sårförband

Legal Events

Date Code Title Description
8364 No opposition during term of opposition